NervGen Pharma Corp.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NGENF research report →
Price Chart
About the company
NervGen Pharma Corp. , including its affiliated entities, is focused on discovering, advancing, and bringing to market pharmaceutical solutions designed to address medical conditions arising from damage to the nervous system. Their primary experimental compound, NVG-291, is currently undergoing Phase 1 clinical trials to assess its potential effectiveness for spinal cord injuries (SCI), multiple sclerosis, and Alzheimer's disease.
- CEO
- Adam H. Rogers
- IPO
- 2019
- Employees
- 11
- HQ
- Vancouver, BC, CA
Get TickerSpark's AI analysis on NGENF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $312.89M
- P/E
- -8.41
- Fwd P/E
- 385.41
- PEG
- 0.12
- P/S
- 0.00
- P/B
- 108.37
- EV/EBITDA
- -15.42
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -17536.81%
- ROIC
- -719.57%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-58,231+59.8%
- Op Income
- $-24,931,994
- Net Income
- $-24,005,895-7.3%
- EPS
- $-0.36+5.3%
- OCF Growth
- -49.1%
- FCF Growth
- -47.3%
- 52W High
- $6.30
- 52W Low
- $1.50
- 50D MA
- $4.41
- 200D MA
- $3.11
- Beta
- 0.76
- RSI (14)
- 43
- Avg Volume
- 157.91K
No earnings-call transcripts are available for NGENF yet.
- Free Float
- 82.6%
- Shares Outstanding
- 79.21M
- Float Shares
- 65.45M
Our NGENF coverage
Recent articles, reports, and earnings notes.
No research on NGENF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NGENF report →NervGen Pharma to Present at Unite2Fight Paralysis' 20th Annual Science and Advocacy Symposium
globenewswire.com · Feb 11
NervGen Pharma Appoints Adam Rogers as Chief Executive Officer to Continue Leading the Company's Growth and Execution of Its Mission in Spinal Cord Injury
globenewswire.com · Feb 9
NervGen Pharma Begins Trading on Nasdaq Today
globenewswire.com · Jan 8
NervGen Pharma Announces Filing of Form F-10 Registration Statement with The SEC Under MJDS
newsfilecorp.com · Dec 17
NervGen Pharma Announces Proposed Amendment to Warrants
newsfilecorp.com · Dec 12
NervGen Pharma Reports Third Quarter Financial Results and Provides Business Updates
newsfilecorp.com · Nov 24
NervGen Pharma Announces Expanded CONNECT SCI Study Data Demonstrating Unprecedented Durable Improvement in Function, Independence, and Quality of Life in Chronic Spinal Cord Injury
newsfilecorp.com · Nov 24
NervGen Pharma Announces Closing of US$10 Million Non-Brokered Private Placement to Support Anticipated Nasdaq Listing and Advance NVG-291 Development
newsfilecorp.com · Nov 19
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.